Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BioRay Approved to Launch Anruixi, a CD20 mAb, for B-Cell Lymphoma in China

publication date: Sep 13, 2023

Zhejiang BioRay Pharma was approved for a China launch of its Class I innovative therapeutic biological product, zuberitamab injection (Anruixi®), to treat CD20-positive diffuse large B-cell lymphoma. Anruixi is China's first CD20 Class I mAb. It targets CD20 on the surface of B-cell, leading to B-cell elimination via ADCC and CDC. The company believes its product has a stronger ADCC effect than the competition. Anruixi is the first China-developed Class I anti-CD20 drug approved for China use and BioRay’s sixth marketed product. BioRay is conducting trials of Anruixi for autoimmune diseases, including primary immune thrombocytopenia. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
September 20-21 | Shanghai
September 25-26 | Digital
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China